Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment (NCT06574620) | Clinical Trial Compass
RecruitingNot Applicable
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
Canada200 participantsStarted 2025-11-28
Plain-language summary
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:
* Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC?
* Can the genetic test results provide information about how a tumour will respond to or resist treatment?
Participants will:
* Receive standard chemotherapy to treat their cancer.
* Provide samples of their blood, tissue, and fluid for genetic testing.
* Visit the clinic every 4 weeks for check-ups and tests.
* Complete questionnaires every 12 weeks.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18 years or older.
✓. Histological or radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC.
✓. Medically fit and planned to undergo laparoscopic procedure as part of standard of care.
✓. Able to give informed consent for the study-related procedures performed during laparoscopy.
✓. Age 18 years or older.
✓. Enrolled in the Personalized Oncogenomics (POG) Program at BC Cancer.
✓. Histological and/or radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC. Participants without a histological diagnosis of PDAC must undergo confirmatory histological diagnosis prior to treatment start date.
✓. Medically fit to undergo surgical resection of the primary lesion(s) as judged by the investigator (Resectable and Borderline Resectable Cohorts only).
Exclusion criteria
✕. Presence of distant or lymph node metastases. Individuals with metastatic PDAC are not eligible.
What they're measuring
1
Frequency of comprehensive genomic results returned within 8 weeks of sample collection.
Timeframe: From the date of resection surgery or baseline ctDNA collection until genomic results are available (typically 8 weeks).
✕. Currently receiving adjuvant (Resectable and Borderline Resectable Cohorts) or systemic (Locally Advanced Cohort) anti-cancer therapy (chemotherapy or any other anti-cancer agent) with one exception: pre-operative therapy is permitted.
✕. Not fit for chemotherapy as judged by the investigator.
✕. Presence of brain metastases.
✕. Positive pregnancy test.
✕. Unable to comply with the study assessments and procedures defined in this protocol.
✕. Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol.